Skip to content

Clinical trials

Phase 1/2 Burkitt Lymphoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Burkitt Lymphoma Phase: Phase 1/2 Clear all

122 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20011
20022
20036
20042
20055
20063
20073
20083
20092
20102
20114
20123
20134
20143
20153
20164
20175
20185
20194
20202
20215
202211
20235
20246
20256
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed42
Recruiting22
Terminated20
Unknown status16
Withdrawn13
Active, not recruiting6
Not yet recruiting3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center9
Fred Hutchinson Cancer Center7
National Cancer Institute (NCI)7
Northwestern University5
Masonic Cancer Center, University of Minnesota4
Mayo Clinic4
Shenzhen BinDeBio Ltd.3
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China2
AstraZeneca2
Autolus Limited2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Burkitt Lymphoma122
Lymphoma, Large B-Cell, Diffuse55
Precursor Cell Lymphoblastic Leukemia-Lymphoma54
Lymphoma, Mantle-Cell50
Lymphoma, Follicular49
Lymphoma48
Lymphoma, Non-Hodgkin47
Lymphoma, B-Cell, Marginal Zone41
Leukemia, Lymphocytic, Chronic, B-Cell39
Lymphoma, Large-Cell, Immunoblastic36

Trials

Showing 26 to 50 of 122. Each trial links to its page on Pharma Observatory.

22 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.